Format

Send to

Choose Destination
See comment in PubMed Commons below
Trends Endocrinol Metab. 2005 Jul;16(5):243-8.

Thyrotropin receptor autoantibodies in Graves' disease.

Author information

1
Department of Endocrinology, Diabetes and Rheumatology, Heinrich-Heine-University of Düsseldorf, 40225 Düsseldorf, Germany. schottmt@uni-duesseldorf.de

Abstract

Clinical thyrotoxicosis in Graves' disease patients is caused by thyrotropin receptor (TSHR)-stimulating autoantibodies. The molecular mechanisms of TSHR post-translational modification, TSHR signaling and TSHR-autoantibody interaction are still debatable, and the precise interaction of stimulating and blocking autoantibodies with TSHR is unclear. Recent TSHR epitope studies indicate that binding sites for stimulating and blocking autoantibodies are close together, not on distinct or distant parts of the molecule. Furthermore, new methods to detect TSHR autoantibodies and their clinical use are addressed. Highly sensitive TSHR autoantibody assays are widely available and cost efficient, and their routine clinical use might help in the differential diagnosis of hyperthyroidism and disease outcome prediction in patients with high levels of TSHR autoantibodies.

PMID:
15950483
DOI:
10.1016/j.tem.2005.05.009
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center